Objectives: Ubiquitin specific protease 32 (USP32) is a highly conserved but uncharacterized gene, which has been reported to be associated with growth of breast cancer cells. However, the role of USP32 in human small cell lung cancer (SCLC) has not been uncovered. The aim of this study was to investigate and evaluate the clinical significance of USP32 in patients with SCLC.
| INTRODUCTION
Lung cancer is thought as one of the most common causes of cancerrelated death worldwide with higher incidence, mortality and lower survival rate. 1 As a histological subtype of lung cancer, small cell lung cancer (SCLC) accounts for 13%-15% of lung cancers and considered as the most malignant of all lung cancers, because of its rapid growth and early metastasis. 2, 3 According to the anatomical extent, patients with SCLC are staged as limited disease (LD) or extensive disease (ED). 4 Compared with LD patients, ED patients have shorter survival rate <5%. 5 At present, combined chemotherapy is the standard treatment for SCLC. 6 Despite great progress has been made in the chemotherapeutic treatment, higher rate of rapidly growing drug-resistant metastases is frequent. Therefore, it is uttermost importance to have a deeper understanding of the molecular mechanism underlying SCLC tumorigenesis and seek new therapeutic strategies for SCLC.
Deubiquitinating enzymes (DUBs) play an important role in regulating cellular ubiquitination by catalysing the removal of ubiquitin from substrates and disassembling ubiquitin chains. 7 It is reported there are five related classes, including 100 DUBs were encoded by the mammalian genome. 8 As the largest and most diverse subclass, ubiquitin-specific proteases (USPs) contain two highly conserved short motifs termed the Cys and His boxes and are believed to target specific protein substrates, which have been shown to be involved in cell cycle progression, apoptosis, gene silencing and immune signalling. 9 Recently, more studies have indicated that USPs participate in the pathogenesis of many human diseases, including inflammation and cancer. 10 USP10, as a novel regulator of p53, is constitutively downregulated in renal clear cell carcinoma 11 and also involves in the Ras signal transduction pathway. 12 USP18 is identified as a key regulator of interferon-induced pancreatic beta cell apoptosis. USP22 is a tumour promoter in oral squamous cell carcinoma patients 13 and papillary thyroid carcinoma. 14 In addition to as oncogenes, USP46 has been found to be a tumour suppressor in colon cancer by regulating PHLPPdependent attenuation of Akt signalling.
15
USP32 localizes on chromosome 17q23 and belongs to the USPs family of cysteine proteases. As an ancient and highly conserved gene, USP32 has more than 90% sequence identity to proto-oncogene USP6. 16 Interestingly, USP6 has been reported to be an oncogene as the first DUB to activate tumour promoter NF-κB in aneurysmal bone cyst. 17 In the study of predicting breast cancer metastasis, USP32 is shown to have increased copy number in oestrogen receptor-positive tumours. 18 Moreover, the mRNA levels of USP32 were also reported to be upregulated in malignant breast epithelium. 19 Shiva et al. 20 have
reported that USP32 is overexpressed in breast cancer, and involved in the proliferation of tumour cells. However, there has been no definitive data showing the expression and biological function of USP32 in SCLC.
Thus, the objective of this study was to investigate whether USP32 is overexpressed by SCLC tissues analysis and online data-mining, and whether USP32 plays a crucial role in regulating tumour cell biological function, in an attempt to gain novel insights into tumorigenesis of SCLC.
| MATERIALS AND METHODS

| Gene expression data sets analysis
To investigate the expression of USP32 in lung cancer, USP32 gene expression was analysed using microarray gene expression data sets derived from the Oncomine database (http://www.oncomine.org).
Briefly, the cancer type was defined as lung cancer, data type was mRNA and analysis type was cancer vs normal analysis. In addition, five sets of USP32 mRNA expression data were downloaded from the Cancer Genome Atlas project (TCGA data set, https://gdc-portal.nci.
nih.gov/) database, including lung adenocarcinoma (LUAD), gastric adenocarcinoma (STAD), breast cancer (BRCA), oesophageal squamous carcinoma (ESCC), and stomach and oesophageal carcinoma (STES).
The expression of USP32 was regarded to be significantly differentially expressed using cut-off criteria of P-value <.05 by t-test method. 
| SCLC tissue specimens and cell lines
| Western blot analysis
Total cell lysates were isolated from tissues samples and cell lines using RIPA lysis buffer containing protease inhibitors (Sigma, St.
Louis, MO, USA). Then cell lysates were centrifuged at 12 000 g for 
| Immunohistochemical analysis
The paraffin-embedded sections were dewaxed with xylenes, and re- 21 Finally, the expression of USP32 was classified into two groups, including low (<3) and high (>3) based on the sum of intensity and extent score scaling from 0 to 6. 
| Cell transfection
| CCK-8 assay
| Colony formation assay
Small cell lung cancer cells from different treatments were seeded in a six-well plate in complete medium until the colonies were visible. Then the plates were washed twice in phosphate-buffered saline (PBS) after removing complete medium. The colonies were fixed in 95% ethanol for 10 minutes, dried and then stained with 0.1% crystal violet solution for 10 minutes. The number of colonies (contained >50 cells) was counted. The experiment was performed three times.
| Flow cytometry analysis
Small cell lung cancer cells from different treatments underwent cell cycle analysis using nuclear stain PI and apoptosis analysis using Annexin V-APC/7-AAD apoptosis detection KIT 
| Cell matrigel invasion assay
To further investigate the role of USP32 in SCLC cell metastasis, a matrigel invasion assay was performed using the BiocoatMatrigel Invasion Chamber (BD) in SCLC cells transfected with different recombinants following the manufacturer's protocols. Briefly, cells were seeded into the upper chamber at 4000 cells per well in 100 μL serumfree medium. The lower chamber was added into a chemoattractant.
After incubation for 24 hours, the viable cells in lower surface of the filter were fixed in 4% paraformaldehyde and stained with crystal violet. The cells on the dissected stained membrane were counted in five random fields (100× magnification) under a light microscope. Each matrigel invasion assay was performed three times.
| Statistical analysis
Data were analysed using spss software, version 13.0 and expressed as the mean ± standard deviation (SD) of more than three samples.
The Student's t-test (two-tailed) was used to analyse the differences between two groups and P-value <.05 was considered as a statistical significant difference.
| RESULTS
| USP32 expression is upregulated in lung cancer tissues
To investigate the expression of USP32 in lung cancer, we performed data-mining to compare the gene expression profiles of USP32 between normal and cancer tissues. The results from Oncomine data sets analysis showed USP32 mRNA expression was significantly elevated in human LUAD tissues compared with that in normal tissues using ). These observations highlighted a deregulated expression of USP32 in cancers, especially in lung cancer.
We then examined the mRNA and proteins expression of USP32 in 10 fresh SCLC tumours and their paired adjacent normal tissues.
As shown in Figure 2A ,B, both the mRNA and proteins expression of USP32 were commonly overexpressed in SCLC tissues, which is consistent with the results of the online data sets analysis. Furthermore, we detected the expression of USP32 in 83 paraffin-embedded SCLC samples and 20 normal lung samples by immunohistochemical analy-
sis. Representative photomicrographs of different degrees of USP32
expression intensity are shown in Figure 2C . As shown in Figure 2D , about 45.4% of paraffin-embedded SCLC tissues showed weak staining of USP32 protein, while 37.5% SCLC tissues showed moderate USP32 staining, and 17.1% showed strong staining. In normal tissues, there was existed relatively less moderate and strong staining area compared with that in SCLC tissues.
| Correlation of USP32 expression with clinicopathological features
To evaluate the association between USP32 expression and the clinicopathological outcomes, the 83 patients with SCLC were divided into two groups: low expression (n=38, 45.4%) and high expression (n=45, 54.6%) according to the positive staining intensity as described in Methods. As described in Table 1 , USP32 expression was significantly correlated with disease stage (LD vs ED, P=.004) and microscopic invasion (P=.005). There was no significant correlation between USP32 expression and age or gender.
| USP32 expression was efficiently suppressed in SCLC cells
Subsequently, the protein level of USP32 was detected in six SCLC cell lines using Western blot analysis. As shown in Figure 3A ,B, the protein level of USP32 was more highly expressed in H1688 and GLC4
cells compared with the other four cell lines. Therefore, H1688 and GLC4 were chosen to explore the role of USP32 in proliferation and metastasis in SCLC. To assess the functional role of USP32 on SCLC cells, both H1688 and GLC4 cells were transfected with siUSP32 or scrambled siRNA. As shown in Figure 3C , the mRNA and protein levels of USP32 were significantly downregulated in H1688 cells (P<.001).
Similar results were also found in GLC4 cells after transfection with siUSP32 ( Figure 3D , P<.001), suggesting a satisfactory knockdown efficiency. 
| Silencing of USP32 significantly inhibited cell proliferation
As USP32 has been shown to be overexpressed in SCLC, the present study Subsequently, we evaluated the colony formation ability in both H1688
and GLC4 cells. As illustrated in Figure 4C ,D, the smaller and fewer colonies were observed in siUSP32 groups than control cells in H1688 and 
| Silencing of USP32 induced cell cycle arrested at G0/G1 phase and apoptosis
To uncover the inhibitory effects of USP32 silencing on cellular proliferation, flow cytometry was performed to analyse the cell cycle distribution and apoptosis in GLC4 cells from different treatments. As shown in Figure 5A , representative images indicated that knockdown of USP32 altered cell cycle distribution profiles in GLC4 cells compared with the negative controls (Mock or NC). Quantitative analysis further confirmed the percentages of cells in G0/G1 phase were significantly increased, whereas the number of cells in S phase was significantly decreased in GLC4 cells infected with siUSP32 ( Figure 5B ,
P<.001).
In addition, USP32 silencing decreased the expression levels of CDK4 and Cyclin D1 and slightly elevated the expression level of p21, suggesting that CDK4, Cyclin D1 and p21 play important roles in USP32-induced cell cycle arrest ( Figure 5C ). Interestingly, in the absence of USP32, more cells were remarkably accumulated in the sub-G1 phase, representing apoptotic cells ( Figure 5D , P<.001).
As illustrated in Figure 6A , Annexin V-APC vs 7-AAD plots from the gated cells showed the population corresponding to viable and ( Figure 6C ). Collectively, knockdown of USP32 significantly suppressed cell cycle progression and induced cell apoptosis, which might be a good explanation for cell growth inhibition caused by USP32 silencing.
| Silencing of USP32 by siRNA leading to decreased invasiveness
In the invasion assay, our results showed siUSP32 successfully reduced matrix invasiveness as compared with controls (Mock or NC) in H1688 cells ( Figure 7A ,B, P<.001). To determine the F I G U R E 5 USP32 silencing remarkably induced G0/G1 arrest in GLC4 cells. A, Representative images showed knockdown of USP32 altered cell cycle distribution profiles in GLC4 cells. B, The cell cycle was significantly arrested in G0/G1 phase in SiUSP32 group. C, Western blot analysis of proteins associated with cell cycle regulation in GLC4 cells after USP32 knockdown. D, The percentage of cells in sub-G1 phase was significantly elevated in SiUSP32 group. Mock: untreated cells; NC: cells were treated with scrambled siRNA; SiUSP32: cells were treated with siRNA targeting USP32; all the results are represented as mean ± SD from three independent experiments. **P<.01, ***P<.001 as compared with NC cells; β-actin was used as an internal control mechanism by which USP32 regulates the invasiveness in H1688 cells, we examined the expression levels of E-cadherin and Ncadherin, as markers of epithelial-mesenchymal transition (EMT).
As shown in Figure 7C , USP32 silencing significantly enhanced the expression of E-cadherin, whereas decreased the expression of N-cadherin. 33 . These results were also in agreement with the role of USP39, and also belongs to the USPs family in tumour progression, such as hepatocellular carcinoma 34 and prostate cancer. 35 However, In this study, we showed that USP32 depletion significantly decreased the migration ability of SCLC cells accompanied by increased Ecadherin and decreased N-cadherin expression. These findings suggest the possibility of USP32 knockdown as an approach to control cancer cell metastasis therapy.
| DISCUSSION
| CONCLUSIONS
In summary, we first demonstrated that USP32 was upregulated in SCLC tissues compared with normal tissues. Functionally, USP32 depletion reduced the growth and migration of SCLC cells by regulating the expression of a series of pro-tumorigenesis molecules. However, further investigation was still needed to elucidate whether USP32 is involved in other signalling pathways required for the progression of SCLC, which will help to better understanding tumour progression of SCLC and guide the development of therapeutic targets for SCLC.
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